Novel cancer treatment begins trials

Israel’s Nectin Therapeutics (see here previously) has started human trials of its NTX1088 cancer treatment. NTX1088 blocks the protein PVR expressed by tumors to suppress the immune system. The treatment also restores DNAM-1, needed to activate anti-cancer T & NK cells.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *